Post-tuberculosis lung function impairment
https://doi.org/10.18093/0869-0189-2017-27-3-656-663
Abstract
In most case, lung lesions of different character and extent remain after successful treatment of pulmonary tuberculosis. High tuberculosis morbidity contributes to increasing numbers of patients with post-tuberculosis abnormalities. Pulmonary tuberculosis or its consequences could cause consistent changes of the lung function. Lung function abnormalities in patients survived pulmonary tuberculosis have been reviewed In this article. A high prevalence of such cases provides the need in spirometric testing. Routine identification of patients with post-tuberculosis pulmonary impairment requires revision of recommendations for spirometry use in tuberculosis patients.
About the Authors
O. N. Ots
I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Doctor of Medicine, Professor, Head of Department of Phthisiology, Pulmonology and Thoracic Surgery
tel.: (495) 681-84-22
ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia
M. I. Chushkin
Federal Central Research Institute of Tuberculosis, Russian Medical Science Academy
Multidisciplinary Medical Center of the Central Bank of Russia
Russian Federation
Russian Federation
Doctor of Medicine, Leading Researcher, Department of Functional Diagnosis
physician
tel.: (499)-785-90-48
Yauzskaya alleya 2, Moscow, 107564, Russia
Sevastopol’skiy prospekt 66, Moscow, 117593, Russia
P. V. Struchkov
Federal Institute of Postgraduate Training, Federal Medical and Biological Agency of Russia
Federal Clinical Hospital No.85, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Doctor of Medicine, Professor, Head of Department of Clinical Physiology and Functional Diagnosis
Head of Division of Functional Diagnosis, Clinical hospital No. 85
tel.: (499) 324-45-83
Volokolamskoe shosse 91, Moscow, 123371, Russia
ul. Moskvorech'e 16, Moscow, 1115409, Russia
References
1. WHO. Global tuberculosis report, 2016. Geneva, Switzerland: WHO; 2016. Available at: http://www.who.int/tb/publications/global_report/en/
2. Shilova M.V. Tuberculosis in Russia in 2012 – 2013. Moscow: Promobyuro; 2014 (in Russian).
3. Perel'man M.I. What should be understood as recovery from tuberculosis? Problemy tuberkuleza i bolezney legkikh. 2004; (11): 3 (in Russian).
4. Hicks A., Muthukumarasamy S., Maxwell D., Howlett D. Chronic inactive pulmonary tuberculosis and treatment sequelae: chest radiographic features [Perspective]. Int. J. Tuber. Lung Dis. 2014; 18 (2): 128–133. DOI: 10.5588/ijtld.13.0360.
5. Jordan T.S., Spencer E.M., Davies P. Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology. 2010; 15 (4): 623–628. DOI: 10.1111/j.1440-1843.2010.01749.x.
6. Vil'derman A.M. Chronic non-specific lung diseases and tuberculosis. Kishinev: Shtiintsa; 1988 (in Russian).
7. Long R. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. Chest. 1998; 113 (4): 933–943.
8. Radovic M., Ristic L., Stankovic I. et al. Chronic airflow obstruction syndrome due to pulmonary tuberculosis treated with directly observed therapy – a serious changes in lung function. Med. Arch. 2011; 65 (5): 265–269.
9. Stepanyan I.E. Bronchial obstruction in patients with pulmonary tuberculosis. Tuberkulez i bolezni legkikh. 2013; (4): 6–11 (in Russian).
10. Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26 (5): 948–968. DOI: 10.1183/09031936.05.00035205.
11. Schünemann H.J., Dorn J., Grant B.J. et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000; 118 (3): 656–664.
12. Sin D.D., Wu L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005; 127 (6): 1952–1959.
13. Young R.P., Hopkins R., Eaton T.E. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur. Respir. J. 2007; 30 (4): 616–622. DOI: 10.1183/09031936.00021707.
14. Mannino D.M., Ford E.S., Redd S.C. Obstructive and restrictive lung disease and functional limitation: data from the Third National Health and Nutrition Examination. J. Intern. Med. 2003; 254 (6): 540–547.
15. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Federal Clinical Guidelines On Diagnosis And Treatment Of Chronic Obstructive Pulmonary Disease. Pul'monologiya. 2014; (3): 15–36 (in Russian).
16. Lam K.B., Jiang C.Q., Jordan R.E. et al. Prior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest. 2010; 137 (3): 593–600. DOI: 10.1378/chest.09-1435.
17. Lamprecht B., McBurnie M.A., Vollmer W.M. et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011; 139 (4): 752–763. DOI: 10.1378/chest.10-1253.
18. Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009; 374 (9691): 733–743. DOI: 10.1016/S0140-6736(09)61303-9.
19. Allwood B.W., Myer L., Bateman E.D. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration. 2013; 86 (1); 76–85. DOI: 10.1159/000350917.
20. Caballero A., Torres-Duque C.A., Jaramillo C. et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008; 133 (2): 343–349. DOI: 10.1378/chest.07-1361.
21. Chung K.P., Chen J.Y., Lee C.H. et al. Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clinics (Sao Paulo). 2011; 66 (4): 549–556.
22. Ehrlich R.I., White N., Norman R. et al. Predictors of chronic bronchitis in South African adults. Int. J. Tuberc. Lung Dis. 2004; 8 (3): 369–376.
23. Lee S.W., Kim Y.S., Kim D.S. et al. The risk of obstructive lung disease by previous pulmonary tuberculosis in a country with intermediate burden of tuberculosis. J. Korean Med. Sci. 2011; 26 (2): 268–273. DOI: 10.3346/jkms.2011.26.2.268.
24. Ralph A.P., Kenangalem E., Waramori G. et al. High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena. PLoS One. 2013; 8 (11): e80302. DOI: 10.1371/journal.pone.0080302.
25. Benfield T., Lange P., Vestbo J. COPD stage and risk of hospitalization for infectious disease. Chest. 2008; 134 (1): 46–53. DOI: 10.1378/chest.07-2933.
26. Jick S.S., Lieberman E.S., Rahman M.U., Choi H.K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006; 55 (1): 19–26. DOI: 10.1002/art.21705.
27. Pettit A.C., Kaltenbach L.A., Maruri F. et al. Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. Int. J. Tuberc. Lung Dis. 2011; 15 (7): 906–911. DOI: 10.5588/ijtld.10.0448.
28. Inghammar M., Ekbom A., Engström G. et al. COPD and the risk of tuberculosis – a population-based cohort study. PLoS One. 2010; 5 (4): e10138. DOI: 10.1371/journal.pone.0010138.
29. Inghammar M., Löfdahl C.G., Winqvist N. et al. Impaired pulmonary function and the risk of tuberculosis: a population-based cohort study. Eur. Respir. J. 2011; 37 (5): 1285–1287. DOI: 10.1183/09031936.00091110.
30. Hnizdo E., Singh T., Churchyard. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax. 2000; 55 (1): 32–55.
31. Andrianova A.Yu., Mishin V.Yu., Tikhonov V.A. Post-tuberculosis lung function changes in outpatients of general medical care facilities. Tuberkulez i bolezni legkikh. 2011; (4): 35–36 (in Russian).
32. Dmitrieva K.V., Khrapova V.V., Kusikova L.M. Functional outcomes of pulmonary tuberculosis in adults. Problemy tuberkuleza. 1980; (11): 29–31 (in Russian).
33. Starilova I.P., Dmitrieva L.I., Ozerova L.V. Chronic bronchitis in survivors of pulmonary tuberculosis. Problemy tuberkuleza. 1986; (11): 29–32 (in Russian).
34. Chushkin M.I. Post-tuberculosis lung function abnormalities. Klinicheskaya meditsina. 2013; (2): 38–41 (in Russian).
35. Hwang Y.I., Kim J.H., Lee C.Y. et al. The association between airflow obstruction and radiologic change by tuberculosis. J. Thorac. Dis. 2014; 6 (5): 471–476. DOI: 10.3978/j.issn.2072-1439.2014.04.02.
36. Jung J.W., Choi J.C., Shin J.W. et al. Pulmonary Impairment in Tuberculosis Survivors: The Korean National Health and Nutrition Examination Survey 2008–2012. PLoS One. 2015; 10 (10): e0141230. DOI: 10.1371/journal.pone.0141230.
37. Menezes A.M., Hallal P.C., Perez-Padilla R. et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur. Respir. J. 2007; 30 (6): 1180–1185. DOI: 10.1183/09031936.00083507.
38. Pasipanodya J.G., Miller T.L., Vecino M. et al. Pulmonary impairment after tuberculosis. Chest. 2007; 131 (6): 1817–1824. DOI: 10.1378/chest.06-2949.
39. Plit M.L., Anderson R., Van Rensburg C.E.J. et al. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur. Respir. J. 1998; 12 (2): 351–356. DOI: 10.1183/09031936.98.12020351.
40. Ramos L.M., Sulmonett N., Ferreira C.S. et al. Functional profile of patients with tuberculosis sequelae in a university hospital. J. Bras. Pneumol. 2006; 32 (1): 43–47.
41. Snider G.L., Doctor L., Demas T.A., Shaw A.R. Obstructive airway disease in patients with treated pulmonary tuberculosis. Am. Rev. Respir. Dis. 1971; 103 (5): 625–640. DOI: 10.1164/arrd.1971.103.5.625.
42. Willcox P.A., Ferguson A.D. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir. Med. 1989; 83 (3): 195–198.
43. Amaral A.F., Coton S., Kato B. et al.Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur. Respir. J. 2015; 46 (4): 1104–1112. DOI: 10.1183/13993003.02325-2014.
44. de Vallière S., Barker R.D. Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2004; 8 (6): 767–771.
45. Wang M.L., Avashia B.H., Petsonk E.L. Interpreting periodic lung function tests in individuals: the relationship between 1- to 5-year and long-term FEV1 changes. Chest. 2006; 130 (2): 493–499. DOI: 10.1378/chest.130.2.493.
46. Ko Y., Lee Y.M., Lee H.Y. et al. Changes in lung function according to disease extent before and after pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 2015; 19 (5): 589–595. DOI: 10.5588/ijtld.14.0454.
47. Ross J., Ehrlich R.I., Hnizdo E. et al. Excess lung function decline in gold miners following pulmonary tuberculosis. Thorax. 2010; 65 (11): 1010–1015. DOI: 10.1136/thx.2009.129999.
48. Vargha G. Fifteen year follow-up of lung function in obstructive and non-obstructive pulmonary tuberculosis. Acta Med. Hung. 1983; 40 (4): 271–276.
49. Sharaykina E.N., Danilova L.K., Shul'man A.V., et al. Implementation of GARD initiative at Krasnoyarsk krai (preliminary findings). Pul'monologiya. 2012; (3): 50–54 (in Russian).
50. Shmeleva N.M., Galkin I.V., Sidorova V.P. et al. An ability to improve diagnosis and treatment of lung obstructive diseases in the Northern District of Moscow. Problemy tuberkuleza. 2008; (7): 18–22 (in Russian).
51. Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370 (9589): 741–750. DOI: 10.1016/S0140-6736(07)61377-4.
52. Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 2011; 155 (3): 179–191. DOI: 10.7326/0003-4819-155-3-201108020-00008.
53. Maguire G.P., Anstey N.M., Ardian M. et al. Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting. Int. J. Tuberc. Lung Dis. 2009; 13 (12): 1500–1506.
54. Lamprecht B., Soriano J.B., Studnicka M. et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest. 2015; 148 (4): 971–985. DOI: 10.1378/chest.14-2535.
55. Nelson S.B., LaVange L.M., Nie Y. et al. Questionnaires and pocket spirometers provide an alternative approach for COPD screening in the general population. Chest. 2012; 142 (2): 358–366. DOI: 10.1378/chest.11-1474.
56. Shmelev E.I., Kuklina G.M., Yakimova M.A., et al. Pulmonary tuberculosis and respiratory comorbidity. Pul'monologiya. 2010; (5): 38–40 (in Russian).
Review
For citations:
Ots O.N., Chushkin M.I., Struchkov P.V. Post-tuberculosis lung function impairment. PULMONOLOGIYA. 2017;27(5):656-663. (In Russ.) https://doi.org/10.18093/0869-0189-2017-27-3-656-663
Views:
6688
Email this article 